CG Oncology, Inc. (CGON) Income Statement
CGON 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCGON revenue and net income
Where CGON's revenue goes
2025Each bar shows an amount and its share of revenue. CGON kept −3,985.0% of revenue as net income.
CGON profit margins
CGON growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +254.7% | +176.6% | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CGON quarterly EPS vs estimates
CG Oncology beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.86).
CGON income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.0M | $1.1M | $204,000 | $191,000 | $10.4M |
| Cost of revenue | $4.6M | $82.1M | $45.8M | $15,000 | $10,000 |
| Gross profit | −$607,000 | −$81.0M | −$45.5M | $176,000 | $10.3M |
| Research & development | $116.6M | $82.1M | $45.8M | $29.0M | $18.3M |
| Sales, general & admin | $73.5M | $33.7M | $9.9M | $6.4M | $4.7M |
| Total operating expenses | $190.2M | $33.7M | $9.9M | $35.4M | $23.0M |
| Operating income | −$190.8M | −$114.7M | −$55.4M | −$35.2M | −$12.6M |
| Interest income | $29.9M | $26.6M | $6.9M | — | — |
| Interest expense | — | — | $6.9M | $1,000 | $451,000 |
| Income before taxes | −$161.0M | −$88.0M | −$48.6M | −$35.4M | −$12.8M |
| Net income | −$161.0M | −$88.0M | −$48.6M | −$35.4M | −$12.8M |
| EBITDA | −$159.6M | −$88.0M | −$48.6M | −$35.4M | −$12.4M |
| EPS (diluted) | −$2.07 | −$1.40 | −$0.33 | −$0.53 | — |
| Gross margin | −15.0% | −7,108.3% | −22,327.5% | 92.1% | 99.9% |
| Operating margin | −4,722.1% | −10,067.3% | −27,180.9% | −18,453.4% | −121.7% |
| Net margin | −3,985.0% | −7,729.5% | −23,827.0% | −18,556.5% | −124.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.1M | $2.3M | $1.7M | $0 | $52,000 | $456,000 | $43,000 | $111,000 | $529,000 | $1,000 | $9,000 |
| Cost of revenue | $3.9M | $3.0M | $2.9M | $1.6M | $31.3M | $27.5M | $26.8M | $19.6M | $18.5M | $4,000 | $4,000 | $11.7M |
| Gross profit | −$2.8M | −$1.9M | −$592,000 | $89,000 | −$31.3M | −$27.4M | −$26.3M | −$19.6M | −$18.4M | $525,000 | −$3,000 | −$11.7M |
| Research & development | $54.7M | $43.7M | $30.0M | $27.9M | $31.3M | $27.5M | $26.8M | $19.6M | $18.5M | $17.2M | $15.9M | $11.7M |
| Sales, general & admin | $29.0M | $20.8M | $18.0M | $23.3M | $17.4M | $14.8M | $11.7M | $8.7M | $7.5M | $5.8M | $3.0M | $2.3M |
| Total operating expenses | $83.6M | $64.5M | $48.1M | $51.2M | $17.4M | $14.8M | $11.7M | $8.7M | $7.5M | $23.0M | $18.9M | $2.3M |
| Operating income | −$86.4M | −$66.4M | −$48.7M | −$51.1M | −$48.7M | −$42.2M | −$38.0M | −$28.3M | −$25.9M | −$22.5M | −$18.9M | −$14.0M |
| Interest income | $7.3M | $6.3M | $7.4M | $7.4M | $7.3M | $7.7M | $6.2M | $7.9M | $6.9M | $5.5M | — | $2.3M |
| Income before taxes | −$79.1M | −$60.2M | −$41.3M | −$43.8M | −$41.4M | −$34.5M | −$31.8M | −$20.4M | −$18.9M | −$16.9M | −$16.1M | −$11.8M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | — | −$2.3M |
| Net income | −$79.1M | −$60.2M | −$41.3M | −$43.8M | −$41.4M | −$34.5M | −$31.8M | −$20.4M | −$18.9M | −$16.9M | −$16.1M | −$11.8M |
| EBITDA | −$78.2M | −$59.4M | −$40.5M | −$43.4M | −$41.3M | −$34.4M | −$31.8M | −$20.4M | −$18.9M | −$16.9M | −$16.1M | −$11.8M |
| EPS (diluted) | −$0.90 | −$0.71 | −$0.51 | −$0.57 | −$0.54 | −$0.45 | −$0.46 | −$0.30 | −$0.28 | −$0.36 | −$0.33 | — |
| Gross margin | −239.2% | −173.5% | −25.5% | 5.3% | — | −52,721.2% | −5,777.2% | −45,532.6% | −16,539.6% | 99.2% | −300.0% | −130,288.9% |
| Operating margin | −7,467.7% | −6,130.1% | −2,097.3% | −3,069.0% | — | −81,161.5% | −8,344.1% | −65,802.3% | −23,291.0% | −4,247.4% | −1,893,200.0% | −156,033.3% |
| Net margin | −6,832.8% | −5,558.8% | −1,779.0% | −2,629.5% | — | −66,253.8% | −6,973.2% | −47,453.5% | −17,028.8% | −3,200.8% | −1,611,600.0% | −130,755.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CGON's financial statements (latest annual report filed February 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CGON financial results
In fiscal year 2025 (ended December 31, 2025), CG Oncology reported revenue of $4.0 million, up 254.7% from the year before. It had a net loss of $161.0 million, a net profit margin of −3,985.0%. Diluted earnings per share came to −$2.07.
See the CGON stock overview for the latest quote and news, or the CGON chart for price history and technical indicators.
CGON income statement FAQ
What is CG Oncology's annual revenue?
CG Oncology reported total revenue of $4.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 254.7% from $1.1 million the previous year.
Is CG Oncology profitable?
No. CG Oncology reported a net loss of $161.0 million in fiscal 2025, a net profit margin of −3,985.0%; its operating margin was −4,722.1%.
What is CG Oncology's gross margin?
CG Oncology's gross margin was −15.0% in fiscal 2025: for every $100 of revenue, CG Oncology kept $-15 after the direct cost of its products and services.
How much does CG Oncology spend on research and development?
CG Oncology spent $116.6 million on research and development in fiscal 2025, 2,887.2% of revenue.
What are CG Oncology's earnings per share?
CG Oncology earned $-2.07 per diluted share in fiscal 2025, compared with $-1.40 a year earlier.
When will CG Oncology report its next earnings?
CG Oncology is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does CG Oncology's fiscal year end?
CG Oncology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 27, 2026.